Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1671502 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $4.40Day +2.92%Mkt cap $14.8B1Y −42.4%Off 52W high −89.5%Vol (1Y) 194.6%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,185 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover3.9d |
| 13F net flow (QoQ)+0.00% |
| Top-10 13F concentration85.8% |
| Next report (est.)2026-08-06 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$17.0M |
| ROE−141.6% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−69.5% |
| 1Y−42.4% |
| 3Y−98.4% |
| Since incept. (ann.)−86.5% |
Total return through 2026-07-30 · series begins 2021-10-29. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)194.6% |
| Ann. volatility (3Y)143.9% |
| Sharpe (1Y)0.39 |
| Sharpe (3Y)−0.37 |
| Max drawdown (1Y)−85.4% |
| Max drawdown (3Y)−98.8% |
| Beta (3Y vs SPY)0.86 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Ikarian Capital, LLC | 211,538 | $1M | — | +0.0% |
| Dauntless Investment Group, LLC | 196,592 | $1M | — | new |
| SummitTX Capital, L.P. | 100,300 | $661,980 | — | +54.8% |
| Velan Capital Investment Management LP | 84,849 | $560,003 | — | new |
| Woodline Partners LP | 79,582 | $525,241 | — | +0.0% |
| MILLENNIUM MANAGEMENT LLC | 76,247 | $503,230 | — | +1.9% |
| Aberdeen Group plc | 75,000 | $495,000 | — | +0.0% |
| Soleus Capital Management, L.P. | 72,730 | $480,018 | — | +190.9% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. % of shares outstanding not shown: no SEC cover-page share count falls within 120 days of the 2026-Q1 quarter end, so any percentage would rest on a count that cannot speak for this quarter. Holder share counts are shown as filed.
No reported quarters on file for QNRX.
